Upon KRAS G12C inhibition, subpopulations of cancer cells that enter a quiescent state can stimulate a compensatory increase in active, GTP-bound KRAS G12C protein via EGFR and aurora kinase signaling. The gene discussed is EGFR; the disease is cancer.